Futec Biomedical Investments

Futec Biomedical Investments Limited was the specialized healthcare investment vehicle of the HeungKong Group, a prominent Chinese private conglomerate. The firm focused on early-stage venture capital investments in the life sciences and biotechnology sectors, particularly in companies developing innovative therapeutic platforms. Notable activities include leading the 2018 seed financing round for DotBio, a domain antibody specialist, and participating in the pre-B round for EdiGene, a genome editing company. While the specific BVI-registered entity was reported as struck off the register in late 2022, it represented the HeungKong Group's strategic entry into the global biomedical innovation landscape.